Last reviewed 2026-04-23 · How we verify

Biological: AL0206st

Allergopharma GmbH & Co. KG · Phase 2 active Small molecule

Biological: AL0206st is a Small molecule drug developed by Allergopharma GmbH & Co. KG. It is currently in Phase 2 development.

At a glance

Generic name	Biological: AL0206st
Sponsor	Allergopharma GmbH & Co. KG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open Label Safety Study of a Birch Pollen Allergen Extract (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Biological: AL0206st CI brief — competitive landscape report
Biological: AL0206st updates RSS · CI watch RSS
Allergopharma GmbH & Co. KG portfolio CI

Frequently asked questions about Biological: AL0206st

What is Biological: AL0206st?

Biological: AL0206st is a Small molecule drug developed by Allergopharma GmbH & Co. KG.

Who makes Biological: AL0206st?

Biological: AL0206st is developed by Allergopharma GmbH & Co. KG (see full Allergopharma GmbH & Co. KG pipeline at /company/allergopharma-gmbh-co-kg).

What development phase is Biological: AL0206st in?

Biological: AL0206st is in Phase 2.

Manufacturer: Allergopharma GmbH & Co. KG — full pipeline
Compare: Biological: AL0206st vs similar drugs
Pricing: Biological: AL0206st cost, discount & access